Penumbra, Inc. (PEN) key performance indicators and operating metrics (16 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Global embolization and access revenue | 120.8M | FY2026-Q1 |
| U.S. revenue | 296.39M | FY2026-Q1 |
| Gross margin (GAAP) | 68.00 percent | FY2025-Q4 |
| Operating margin (GAAP) | 15.40 percent | FY2025-Q4 |
| Adjusted earnings before interest, taxes, depreciation and amortization | 79.1M | FY2025-Q4 |
| Adjusted earnings before interest, taxes, depreciation and amortization margin | 20.50 percent | FY2025-Q4 |
| U.S. thrombectomy revenue | 203.1M | FY2025-Q4 |
| Global thrombectomy products revenue | 254.7M | FY2025-Q4 |
| Global embolization and access products revenue | 130.7M | FY2025-Q4 |
| U.S. share of total revenue | 77.60 percent | FY2025-Q4 |
| International share of total revenue | 22.40 percent | FY2025-Q4 |
| Net income margin (GAAP) | 12.30 percent | FY2025-Q4 |
| Gross margin | 66.00 percent | FY2025-Q2 |
| Net income margin | 13.30 percent | FY2025-Q2 |
Back to PEN overview · PEN earnings · PEN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.